COMBINATION OF A WEE1 INHIBITOR AND A TOPOISOMERASE 1 INHIBITOR

AR135393A1Pending Publication Date: 2026-09-02DEBIOPHARM INTERNATIONAL SA

0 Cites 0 Cited by

Patent Information

Application Number: ARP20250100591
Authority / Receiving Office: AR · AR
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2024-09-23
Filing Date: 2025-03-05
Publication Date: 2026-09-02

Application Information

Patent Timeline

23 Sep 2024

Priority

05 Mar 2025

Application

ARP20250100591

02 Sep 2026

Publication

AR135393A1

IPC: A61K31/4745; A61K45/06; A61K47/50; A61K47/68; A61P35/00

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Need to check novelty before this filing date? Find Prior Art

No text content released.

Claims

Methods for treating cancer using a combination of a WEE1 inhibitor and a topoisomerase 1 inhibitor are provided.

1. Combination of a WEE1 inhibitor and at least one drug selected from a topoisomerase 1 inhibitor and an antibody-drug conjugate (ADC) characterized in that it comprises a topoisomerase 1 inhibitor.

7. Combination according to claim 1, combination for use according to claim 2 or 3, WEE1 inhibitor for use according to claim 4, topoisomerase 1 inhibitor for use according to claim 5, or ADC for use according to claim 6, characterized in that the WEE1 inhibitor is a compound of formula (1), or a pharmaceutically acceptable salt thereof.